Pfizer and BioNTech Report Results of COVID-19 Vaccine Booster in P-III Trial for the Treatment of COVID-19
Shots:
- The P-III trial evaluates a booster dose of COVID-19 vaccine (30µg) in a ratio (1:1) in 10000+ individuals aged ≥16yrs. with COVID-19 who previously received the primary two-dose series of vaccine
- The results showed vaccine efficacy of 95.6% compared to a non-boosted group- median time b/w second & booster dose was ~11mos.- symptomatic COVID-19 occurrence was measured from 7 days after booster with a median follow-up of 2.5mos.- AEs profile was consistent with other clinical safety data for vaccine & no safety concerns were observed
- The companies also plan to share the data with the US FDA- EMA & other regulatory agencies globally to support license in the US & other countries shortly
Ref: Pfizer | Image: Hindustan Times
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com